2026-10-12T12:38:22Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33790169 2026-09-15T11:49:56Z category_37339 category_37360 category_37375 portal_1012 item_type_3 month_year_09_2026

Table 1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors Zhaopeng Sun (24930593) Mo Dan (24930596) Lu Lv (24930599) Mingyue Shen (24930602) Can Yuan (24930605) Congcong Niu (24930608) Yang Zhang (24930611) Xixin Hu (24930614) Xiwu Hui (24930617) Andrew Kolodziej (24930620) Cancer Therapeutic Research and Development Methods and Technology Antibody-drug Conjugates Biological Agents & Therapies Cell Cycle Mechanisms Of Anticancer Drug Action Cell Surface Receptor Drug Targets Drug Mechanisms Drug Targets Preclinical Models Xenograft Models <p>Mean PK of ADC, tAb, and MMAE analytes following a single intravenous dose of CRB-701 or EV in Sprague–Dawley rats and cynomolgus monkeys.</p> 2026-09-15T00:00:00Z Dataset Dataset 10.1158/2767-9764.33790169 https://figshare.com/articles/dataset/Table_1_from_CRB-701_A_Second-generation_Nectin-4_Targeted_Antibody_Drug_Conjugate_with_Optimized_Stability_and_Pharmacokinetics_for_the_Treatment_of_Solid_Tumors/33790169 CC BY